BioCentury
ARTICLE | Company News

Veteran Roche cancer executive O'Day to lead Gilead

December 14, 2018 9:17 PM UTC

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he becomes chairman and CEO of Gilead Sciences Inc. (NASDAQ:GILD) next spring.

Genentech Inc. CEO Bill Anderson will succeed O’Day as CEO of the Roche (SIX:ROG; OTCQX:RHHBY) pharmaceuticals division on Jan. 1. O’Day, who will step down Dec. 31, will provide support for the transition until he joins Gilead March 1 (see "Genentech's Anderson to Succeed O'Day at Roche")...